Clinical Trial Update: Study Using WST11 in Patients With Non-Resectable or Inoperable Cholangiocarcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating WST11 (padeliporfin) for non-resectable or inoperable cholangiocarcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• WST11 (padeliporfin) (padeliporfin)

Snippet

Sponsor: Steba Biotech S.A. | Conditions: Cholangiocarcinoma | Phase 2 | Status: TERMINATED